#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean
A little more than a year after Yescarta was approved as the first CAR-T for third-line therapy in large B-cell lymphoma, researchers are still trying to determine what the median overall survival rate for patients is. It hasn’t been reached.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.